Jonathan I. Lieber, Chief Financial Officer of Rallybio Corp, filed a statement of changes in beneficial ownership on October 28, 2026, reporting two transactions in Rallybio common stock on October 26 and October 27, 2026.

Key Highlights

  • Acquisition: Lieber acquired 2,500 shares of Rallybio common stock on October 26, 2026, at a price of $0, bringing his direct holdings to 16,150 shares.
  • Disposition: Lieber sold 599 shares on October 27, 2026, at a price of $16.04 per share, reducing his direct holdings to 15,551 shares.
  • Purpose of sale: According to the filing, the 599 shares were sold "solely to satisfy tax withholding obligations incurred upon vesting" of a performance stock award.
  • Reporting person role: Lieber is identified in the filing as Chief Financial Officer of Rallybio Corp, listed on NASDAQ:RLYB.
  • No derivative securities: No derivative security transactions were reported in this filing.

CFO Jonathan Lieber's October 2026 Transactions in Rallybio Common Stock

According to the filing, Jonathan I. Lieber, who serves as Chief Financial Officer of Rallybio Corp, reported two transactions in the company's common stock occurring on consecutive days. On October 26, 2026, Lieber acquired 2,500 shares through a transaction coded "A" at a price of $0, consistent with the partial vesting of a performance stock award. Following that acquisition, his direct beneficial ownership stood at 16,150 shares of common stock.

On October 27, 2026, the filing reports that Lieber disposed of 599 shares at $16.04 per share through a sale coded "S." The filing's footnote explains that this sale was made "upon the partial vesting of a performance stock award, solely to satisfy tax withholding obligations incurred upon vesting." After this transaction, Lieber's direct beneficial ownership in Rallybio common stock totaled 15,551 shares. All reported holdings are held directly.

Rallybio Corp is a biopharmaceutical company. The filing was signed by Stephen Uden as Attorney-in-Fact on October 28, 2026, and covers only non-derivative securities. Table II, covering derivative securities such as options or warrants, reflects no reportable transactions by Lieber in connection with these events.

What Was Disclosed

The filing disclosed that Rallybio Corp's CFO, Jonathan I. Lieber, acquired 2,500 shares at $0 on October 26, 2026, through a performance stock award vesting, then sold 599 of those shares at $16.04 on October 27, 2026, to cover tax withholding, leaving him with 15,551 shares held directly.